由CYP2C19指导的抗血小板疗法是治疗点的药物遗传学加上多维治疗决策
Victor Voicu1,2, Nicolas Diehm3, Igal Moarof4
1Swiss Federal Institute of Technology Zurich (ETHZ), Switzerland.
Pharmacogenomics
|January 17, 2024
概括
对CYP2C19的临床药物遗传学 (PGx) 测试可靠地指导个性化抗血小板治疗. 这种方法为根据遗传变异和患者因素调整治疗提供了即时的临床益处.
科学领域:
- 药物基因组学 药物基因组学
- 临床化学 临床化学
- 个性化医疗是个性化的医疗.
背景情况:
- 抗血小板治疗是复杂的,需要个性化的方法.
- CYP2C19遗传变异显著影响药物反应.
- 临床检测提供了快速的遗传信息.
研究的目的:
- 在 point-of-care 实施和评估 CYP2C19 药物遗传学 (PGx) 测试.
- 评估POC PGx测试用于指导抗血小板治疗的可靠性.
- 确定立即基于PGx的治疗建议的临床效用.
主要方法:
- 在167名患者中进行POC CYP2C19基因型鉴定.
- 对缺血和出血事件的评估患者特异性风险因素.
- 将POC PGx结果与CYP2C19变异的标准分析进行比较 (*2, *3).
主要成果:
- 54% (32.3%) 的患者是CYP2C19功能丧失的载体.
- POC和标准PGx分析显示,对*2和*3变体的一致性为100%.
- 44名患者 (26.3%) 的抗血小板治疗根据PGx和临床因素进行调整.
结论:
- CYP2C19 POC-PGx测试可靠且在临床上有利于立即调整抗血小板治疗.
- 个性化抗血小板治疗需要将PGx数据与专家临床知识相结合.
- 虽然POC测试提供了急性益处,但对于不那么紧急的病例,传统的PGx测试可能就足够了.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
01:26Peptic Ulcer Disease IV: Management
94
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
94
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183